厚朴酚
自噬
化学
药理学
细胞凋亡
脚手架
立体化学
生物化学
医学
色谱法
生物医学工程
作者
Min Zhao,Yunhua Zheng,Qiyuan Zhao,Wei Zheng,Jianhong Yang,Heying Pei,Ling Liu,Kongjun Liu,Linlin Xue,Dexin Deng,Lun Wang,Xu Ma,Suhong Fu,Aihua Peng,Minghai Tang,Yunzi Luo,Haoyu Ye,Lijuan Chen
标识
DOI:10.1016/j.ejmech.2020.112922
摘要
Magnolol and honokiol are the two major active ingredients with similar structure and anticancer activity from traditional Chinese medicine Magnolia officinalis, and honokiol is now in a phase I clinical trial (CTR20170822) for advanced non-small cell lung cancer (NSCLC). In search of potent lead compounds with better activity, our previous study has demonstrated that magnolol derivative C2, 3-(4-aminopiperidin-1-yl)methyl magnolol, has better activity than honokiol. Here, based on the core of 3-(4-aminopiperidin-1-yl)methyl magnolol, we synthesized fifty-one magnolol derivatives. Among them, compound 30 exhibited the most potent antiproliferative activities on H460, HCC827, H1975 cell lines with the IC50 values of 0.63-0.93 μM, which were approximately 10- and 100-fold more potent than those of C2 and magnolol, respectively. Besides, oral administration of 30 and C2 on an H460 xenograft model also demonstrated that 30 has better activity than C2. Mechanism study revealed that 30 induced G0/G1 phase cell cycle arrest, apoptosis and autophagy in cancer cells. Moreover, blocking autophagy by the autophagic inhibitor enhanced the anticancer activity of 30in vitro and in vivo, suggesting autophagy played a cytoprotective role on 30-induced cancer cell death. Taken together, our study implied that compound 30 combined with autophagic inhibitor could be another choice for NSCLC treatment in further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI